Literature DB >> 455821

Uremic middle molecules exist and are biologically active.

J Bergström, P Fürst, L Zimmerman.   

Abstract

Mesh:

Substances:

Year:  1979        PMID: 455821

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


× No keyword cloud information.
  9 in total

Review 1.  Recent advances in the pathogenesis and nutritional treatment of chronic uremia.

Authors:  P Fürst; A Alvestrand; J Bergström
Journal:  Z Ernahrungswiss       Date:  1982-09

2.  Middle molecular substances in acute renal failure.

Authors:  M Mydlík; V Spustová; R Dzúrik; K Derzsiová
Journal:  Int Urol Nephrol       Date:  1982       Impact factor: 2.370

3.  Peritoneal dialysability of "uraemic substances".

Authors:  I Taraba; V Spustova; A Balás-Eltes; R Dzurik; G Y Petrányi
Journal:  Int Urol Nephrol       Date:  1981       Impact factor: 2.370

Review 4.  The membrane perspective of uraemic toxins: which ones should, or can, be removed?

Authors:  Sudhir K Bowry; Peter Kotanko; Rainer Himmele; Xia Tao; Michael Anger
Journal:  Clin Kidney J       Date:  2021-12-27

5.  End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen.

Authors:  D R Sell; V M Monnier
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

6.  Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure.

Authors:  M Magnusson; K E Magnusson; T Sundqvist; T Denneberg
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

7.  Characterization and partial purification of a factor from uremic human serum that induces insulin resistance.

Authors:  M L McCaleb; M S Izzo; D H Lockwood
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane.

Authors:  D R Sell; E C Carlson; V M Monnier
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

9.  Immunomodulating properties of the uremic pentapeptide H-Asp-Leu-Trp-Glu-Lys-OH in vitro.

Authors:  D Niese; K Gilsdorf; E Hiester; P Dressen; S Michels; H J Dengler
Journal:  Klin Wochenschr       Date:  1986-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.